CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0333 (clinicaltrials.gov NCT No: NCT01498445)
Title:AN OPEN-LABEL, PHASE I/II STUDY OF TWO DIFFERENT SCHEDULES OF DASATINIB (SPRYCEL) AND DECITABINE (DACOGEN) USED IN COMBINATION FOR PATIENTS WITH ACCELERATED OR BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (Protocol CA180357)
Principal Investigator:Jorge Cortes
Treatment Agent:Dasatinib; Decitabine
Study Status:Open
Study Description:The goal of this clinical research study is to learn if combining Spyrcel
(dasatinib) and Dacogen (decitabine) can help to control CML. The dose level
of decitabine will also be studied.

Dasatinib is designed to block the protein that is responsible for chronic
myeloid leukemia.

Decitabine is designed to affect the mechanism that cells use to control the
expression of certain genes, some of which are important in the progression of
CML.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Dasatinib
Decitabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:BMS
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults